You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.
Initial data on the PARIS test, combining functional drug testing and DNA sequencing, showed concordance between its predictions and patients' treatment responses.
The startup has exclusively licensed an integration engine from the University of Miami to augment its VIPER platform and improve trial recruitment specifically in precision oncology.
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.
The organoids could be grown to contain cellular features of the original tissue samples, enabling them to better mimic what occurs in the body than two-dimensional cultures.
In patients with Luminal B tumors the CDK4/6 inhibitor ribociclib along with hormonal therapy produced response rates similar to multi-agent chemotherapy.